Skip to content
Our Company
Culture and Values
Leadership
Corporate Impact
Environmental, Social, and Governance
Product Donations
Charitable Giving
CME and Research Grants
Careers
Open Roles
Life at Emergent
Locations
Our Focus
Biological Threats
Opioid Crisis
Manufacturing Partnerships
Our Science
Pipeline
Publications
Our Products
Product and Medical Inquiries
Latest
Press Releases
Blog
Podcast
Media Statements
Media Resources
Investors
FOLLOW US
All Publications
Filter:
Program
Medical Countermeasures
Opioid Antagonist
Filter
August 28, 2013
Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White Rabbits
Read More
May 25, 2013
Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of 4 Formulations of Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909) in Healthy Adult Volunteers
Read More
May 10, 2013
Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis
Read More
January 30, 2013
Pathology and Pathophysiology of Inhalational Anthrax in a Guinea Pig Model
Read More
June 1, 2011
Marked Enhancement of the Immune Response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 Agonist CPG 7909 in Healthy Volunteers
Read More
September 16, 2006
Increased Potency of BioThrax Anthrax Vaccine with the Addition of the C-Class CpG Oligonucleotide Adjuvant CPG 10109
Read More
1
2
3
4
